Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens

Vaccine

Volumn 14, Issue 9, 1996, Pages 898-904

  Phillips, Nigel C ^a   Gagné, Lucie ^b   Ivanoff, Nathalie ^c   Riveau, Gilles ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Advanced Therapies Inc   (United States)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Adjuvant; Alum; IgA; IgE; IgG; IgG(2a); IgG(2b); Liposome; MDP; zeta potential

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIPOSOME; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030174295     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(96)82949-5     Document Type: Article

References (46)

1. 1 Gregoriadis, G., Davis, D. and Davies, A. Liposomes as immunological adjuvants: antigen incorporation studies. Vaccine 1987, 5, 145-151
2. 2 Gregoriadis, G. and Panagiotidi, C. Immunoadjuvant action of liposomes: comparison with other adjuvants. Immunol. Lett. 1989, 20, 237-240
3. 3 Alving, C.R. Liposomes as carriers of antigens and adjuvants. J. Immunol. Meth. 1991, 140, 1-13
4. 4 Shek, P.N. and Sabiston, B.H. Immune response mediated by liposome-associated protein antigens. II. Comparison of the effectiveness of vesicle-entrapped and surface-associated antigen in immunopotentiation. Immunology 1982, 47, 627-632
5. 5 Thérien, H.-M. and Shahum, E. Importance of physical association between antigen and liposome in liposome adjuventicity. Immunol. Lett. 1989, 22, 253-258
6. 6 Thérien, H.-M., Lair, D. and Shahum, E. Liposomal vaccine: influence of antigen association on the kinetics of the humoral response. Vaccine 1990, 8, 558-562
7. 7 Friede, M., Muller, S., Briand, J.P., Van Regenmortel, M.H. and Schuber, F. Induction of immune response against a short synthetic peptide antigen coupled to small neutral liposomes containing monophosphoryl lipid A. Mol. Immunol. 1993, 30, 539-547
8. 8 Phillips, N.C. and Emili, A. Enhanced antibody response to liposome-associated proteins: preferential stimulation of IgG2a/IgG2b production. Vaccine 1992, 10, 151-158
9. 9 Phillips, N.C. Liposomal carriers for the treatment of acquired immune deficiency syndromes. Bull. Inst. Pasteur 1992, 90, 205-230
10. 10 Phillips, N.C. Impaired stimulation of anti-bovine serum albumin IgG antibodies by vaccine adjuvants in murine acquired immunodeficiency syndrome. FEMS Microbiol. Immunol. 1992, 89, 209-218
11. 11 Phillips, N.C., Major, P.P. and Sikorska, H. Tumor-associated antigens as immunotherapy targets. Cancer Detect. Prevent. 1988, 12, 451-459
12. 12 Phillips, N.C., Loutfi, A., A-Kareem, A.M., Shibata, H.R. and Baines, M.G. Clinical evaluation of liposomal tumor antigen vaccines in patients with stage-III melanoma. Cancer Detect. Prevent. 1990, 14, 491-496
13. 13 Fidler, I.J., Sone, S., Fogler, W.E. et al. Efficacy of liposomes containing a lipophilic derivative for activating the tumoricidal properties of alveolar macrophages in vivo. J. Biol. Resp. Modif. 1982, 1, 43-55
14. 14 Kleinerman, E.S., Murray, J.L., Snyder, J.S., Cunningham, J.E. and Fidler, I.J. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Res. 1989, 49, 4665-4670
15. 15 Phillips, N.C., Rioux, J. and Tsao, M.S. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide. Hepatology 1988, 8, 1046-1050
16. 16 Ullrich, S.E. and Fidler, I.J. Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens. J. Leukocyte Biol. 1992, 52, 489-494
17. 17 Bui, T., Dykers, T., Hu, S.L., Faltynek, C.R. and Ho, R.J. Effect of MTP-PE liposomes and interleukin-7 on induction off anti-body and cell-mediated immune responses to a recombinant HIV-envelope protein. J. AIDS 1994, 7, 799-806
18. 18 Ho, D.D., Kaplan, J.C., Rackauskas, I.E. and Gurney, M.E. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science 1988, 239, 1021-1023
19. 19 Boulanger, D., Reid, G.D., Sturrock, R.F. et al. Immunization of mice and baboons with the recombinant Sm28GST affects both worm viability and fecundity after experimental infection with Schistosoma mansoni. Parasite Immunol. 1991, 13, 473-490
20. 20 Phillips, N.C. and Emili, A. Immunogenicity of immunoliposomes. Immunol. Lett. 1991, 30, 291-296
21. 21 Shahum, E. and Thérien, H.-M. Immunopotentiation of the humoral response by liposomes: encapsulation versus linkage. Immunology 1988, 65, 315-317
22. 22 Phillips, N.C. and Dahman, J. Immunogenicity of immunoliposomes: reactivity against species-specific IgG and liposomal phospholipids. Immunol. Lett. in press
23. 23 Van Rooijen, N. and van Nieuwmegen, R. Use of liposomes as biodegradable and harmless adjuvants. Meth. Enzym. 1983, 93, 83-95
24. 24 Parnham, M.J. and Wetzig, H. Toxicity screening of liposomes. Chem. Phys. Lipids 1993, 64, 263-274
25. 25 Bakouche, Q., David, F. and Gerlier, D. Impairment of immunogenicity by antigen presentation in liposomes made from dimyristoylphosphatidylethanolamine linked to the secretion of prostaglandins by macrophages. Eur. J. Immunol. 1987, 17, 1839-1842
26. 26 Phillips, N.C., Moras, M.L., Chedid, L., Lefrancier, P. and Bernard, J.M. Activation of alveolar macrophage tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res. 1985, 45, 128-134
27. 27 Kleinerman, E.S., Raymond, A.K., Bucana, C.D. et al. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol. Immunother. 1992, 34, 211-220
28. 28 Pelassy, C., Aussel, C. and Fehlmann, M. Phospholipid metabolism and T cell activation: receptor triggering is associated with the inhibition of phosphatidylserine synthesis. Cell. Signal. 1989, 1, 99-105
29. 29 Monastra, G. and Bruni, A. Decreased serum level of tumor necrosis factor in animals treated with lipopolysaccharide and liposomes containing phosphatidylserine. Lymph. Cytokine Res. 1992, 11, 39-43
30. 30 Caselli, E., Baricordi, O.R., Melchiorri, L., Bellini, F., Ponzin, D. and Bruni, A. Inhibition of DNA synthesis in peripheral blood mononuclear cells treated with phosphatidylserines containing unsaturated acyl chains. Immunopharmacology 1992, 23, 205-213
31. 31 Phillips, N.C. and Gagné, L. Modulation of murine macrophage nitric oxide synthesis by liposomal phospholipids: correlation with liposome immune adjuvant activity. J. Drug Targeting 1995, 3, 137-147
32. 32 Girolomoni, G., Pastore, S., Zacchi, V., Cavani, A., Marconi, A. and Giannetti, A. Phosphatidylserine enhances the ability of epidermal Langerhans cells to induce contact hypersensitivity. J. Immunol. 1993, 150, 4236-4243
33. 33 Mosior, M. and Epand, R.M. Mechanism of activation of protein kinase C: roles of diolein and phosphatidylserine. Biochemistry 1993, 32, 66-75
34. 34 Chaicumpa, W., Parairo, J.R., New, R.C. et al. Immunogenicity of liposome-associated oral cholera vaccine prepared from combined Vibrio cholerae antigens. Asian Pacific J. Allergy Immunol. 1990, 8, 87-94
35. 35 Brownlie, R.M., Brahmbhatt, H.N., White, D.C. et al. Stimulation of secretory antibodies against Bordetella pertussis antigens in the lungs of mice after oral or intranasal administration of liposome-incorporated cell-surface antigens. Microbial Pathogenesis 1993, 14, 149-160
36. 36 Vadolas, J., Davies, J.K., Wright, P.J. and Strugnell, R.A. Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur. J. Immunol. 1995, 25, 969-975
37. 37 Dreesman, G.R., Sanchez, Y., Ionescu-Matiu, I. et al. Antibody to hepatitis B surface antigen after a single inoculation of uncoupled synthetic HBsAg peptides. Nature 1982, 295, 158-160
38. 38 Kahn, J.O., Sinangil, F., Baenziger, J. et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1 SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J. Infect. Dis. 1994, 170, 1288-1291
39. 39 Burke, R.L., Goldbeck, C., Ng, P., Stanberry, L., Ott, G. and Van Nest, G. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J. Infect. Dis. 1994, 170, 1110-1119
40. 4 potentiate the antigen-presenting capacity of macrophages. Immunopharmacology 1989, 18, 107-113
41. 41 Gajewski, T.F., Pinnas, M., Wong, T. and Fitch, F.W. Murine Th1 and Th2 clones proliferate optimally in response to distinct antigen-presenting cell populations. J. Immunol. 1991, 146, 1750-1758
42. 42 Bromander, A., Holmgren, J. and Lycke, N. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. Cell. Immunol. 1991, 146, 2908-2914
43. 43 Liu, D., Wada, A. and Huang, L. Potentiation of the humoral response of intravenous antigen by splenotropic liposomes. Immunol. Lett. 1992, 31, 177-182
44. 44 Harding, C.V., Collins, D.S., Kanagawa, O. and Unanue, E.R. Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation. J. Immunol. 1991, 147, 2860-2863
45. 45 Lopes, L.M. and Chain, B.M. Liposome-mediated delivery stimulates a class I-restricted cytotoxic T cell response to soluble antigen. Eur. J. Immunol. 1992, 22, 287-290
46. 46 Vajdy, M., Kosco-Vilbois, M.H., Kopf, M., Köhler, G. and Lycke, N. Impaired mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med. 1995, 181, 41-53